Background Immunohistochemical markers are often used to classify breast cancer into
subtypes that are biologically distinct and behave differently. The aim of this study was to …

Abstract Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target
the BRAF or MEK kinases can be effective, but resistance develops invariably 1 , 2 . In …

Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …

Episialin (MUC1) is a transmembrane molecule with a large mucin-like extracellular domain
protruding high above the cell surface. The molecule is located at the apical side of most …

The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer
(ENVISION) brings together several international research consortia working on different …

Objective: The MARI procedure [marking the axillary lymph node with radioactive iodine (125
I) seeds] is a new minimal invasive method to assess the pathological response of nodal …

Episialin (MUC1, PEM, EMA, CA15-3 antigen) is a sialylated, membrane-associated
glycoprotein with an extended mucin-like ectodomain. This domain mainly consists of 30-90 …

Mutations in the chromatin remodeling gene ARID1A have recently been identified in the
majority of ovarian clear cell carcinomas (OCCCs). To determine the prevalence of mutations in …

… Rodenhuis, Jelle Wesseling, Marie-Jeanne TFD Vrancken Peeters Collection and
assembly of data: Claudette E. Loo, Marieke E. Straver, Jelle Wesseling, Kenneth GA …

Background The current debate on overdiagnosis and overtreatment of screen-detected
ductal carcinoma in situ (DCIS) urges the need for prospective studies to address this issue. A …